American Physicians Services ( AMPH) downgraded at Raymond James to Underperform from Outperform following announced $32.50/share takeover by ProAssurance.

Camelot Information Systems ( CIS) initiated at Goldman with a Neutral rating.

Clearwire ( CLWR) initiated at Kaufman Brothers with a Buy rating and $8.50 target. Company's wireless data services are set to increase significantly in 2011.

Education Realty Trust ( EDR) initiated at Hillard Lyons with a Neutral rating. Student housing sector attractive for several reasons, but EDR is fairly valued.

EZchip Semiconductor ( EZCH) initiated at Barclays with an Overweight rating and $30 price target. Fast growing market, complex products with long design cycles.

FormFactor ( FORM) upgraded at Goldman to Neutral from Sell.

Hewlett-Packard ( HPQ) upgraded at JMP Securities to Outperform from Market Perform.

Mellanox Technologies ( MLNX) initiated at Barclays with an Equal Weight rating and $20 price target. 2Q disappointment will continue to weight on the stock at least until next results announcement.

Nice Systems ( NICE) initiated at Barclays with an Overweight rating and $37 price target. Nice is benefiting from increasing regulatory requirements, continued spending on security surveillance, and potential to make aggressive acquisitions.

PPL Corp ( PPL) downgraded at Citi to Hold from Buy. Catalysts in rearview mirror and falling commodity prices. Price target cut to $28.50 from $30.50.

QLT Inc ( QLTI) initiated at CK Cooper with a Buy rating and $12 price target. QLTI will continue to be a player in the growing ophthalmology market.

Rio Tinto ( RTP) upgraded at RBC Capital to Outperform from Sector Perform.

Vantage Drilling ( VTG) coverage initiated at Jefferies with a Buy rating.


FormFactor ( FORM) target, estimates slashed at Barclays. FORM price target cut in half to $6 from $12. 2010 and 2011 EPS estimates lowered to -$2.30 and -$1.60, respectively. Cash burn continues.

Joy Global ( JOYG) target, estimates boosted at Barclays. JOYG price target increased to $74 from $70. 2010 and 2011 EPS estimates lifted to $4.15 and $4.65, respectively. 3Q10 results continued a string of strong performances that we expect to continue.

Monsanto ( MON) 2010 estimate trimmed at Citi to $2.42 from $2.58 due to another restructuring charge in Roundup and a shift out of corn and into soybeans in Brazil. Maintain Buy rating and $62 price target.

This article was written by a staff member of TheStreet.